Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12568355 | 1.00 | MAP3K7 (0.30) | MAP3K7TAB1 | |
| SCHEMBL12202544 | 1.00 | MAP3K7 (0.30) | MAP3K7TAB1 | |
| SCHEMBL3156583 | 0.86 | APAF1 (0.40) | — | |
| SCHEMBL3670921 | 0.86 | APAF1 (0.40) | — | |
| SCHEMBL3159235 | 0.86 | APAF1 (0.40) | — | |
| SCHEMBL10276318 | 0.84 | EPHX1 (0.31) | — | |
| SCHEMBL14821547 | 0.84 | — | — | |
| SCHEMBL26211539 | 0.84 | EPHX1 (0.31) | — | |
| SCHEMBL23152925 | 0.83 | MAP3K7 (0.31) | MAP3K7TAB1 | |
| SCHEMBL12016020 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022272133-A2 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP7 LIGANDS | Stablix, Inc. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022245759-A2 | AGENTS FOR DIRECTED CONJUGATION TECHNIQUES AND CONJUGATED PRODUCTS | BIOHAVEN THERAPEUTICS LTD. (US) | 2022-11-24 | — | — | WO | disclosed |
| US-20210169970-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2021-06-10 | — | — | US | disclosed |
| US-20210163536-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | IPSEN PHARMA SAS (FR) | 2021-06-03 | — | — | US | disclosed |
| US-10954268-B2 | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | RHYTHM PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20190111105-A1 | Use of Melanocortins to Treat Insulin Sensitivity | IPSEN PHARMA S.A.S. (FR) | 2019-04-18 | — | — | US | disclosed |
| EP-2979703-B1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA SAS (FR) | 2018-07-18 | — | — | EP | disclosed |
| US-20180118784-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | IPSEN PHARMA S.A.S. (FR) | 2018-05-03 | — | — | US | disclosed |
| US-9845339-B2 | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | RHYTHM PHARMACEUTICALS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9827286-B2 | Use of melanocortins to treat insulin sensitivity | IPSEN PHARMA S.A.S. (FR) | 2017-11-28 | — | — | US | disclosed |
| US-20120135923-A1 | Use of Melanocortins to Treat Dyslipidemia | IPSEN PHARMA, S.A.S. (FR) | 2012-05-31 | — | — | US | disclosed |
| US-7960349-B2 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960349-B2 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| WO-2011017209-A1 | USE OF MELANOCORTINS TO TREAT DYSLIPIDEMIA | IPSEN PHARMA S.A.S. (FR) | 2011-02-10 | — | — | WO | disclosed |
| US-20100311647-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA S.A.S. (FR) | 2010-12-09 | — | — | US | disclosed |
| WO-2010120476-A2 | N-TERMINUS CONFORMATIONALLY CONSTRAINED GLP-1 RECEPTOR AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20090004264-A1 | METHODS FOR TREATING AND AMELIORATING THE SYMPTONS OF INFLAMMATORY BOWEL DISEASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2009-01-01 | — | — | US | disclosed |
| WO-2008147556-A2 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | IPSEN PHARMA S.A.S. (FR) | 2008-12-04 | — | — | WO | disclosed |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090004264-A1 | METHODS FOR TREATING AND AMELIORATING THE SYMPTONS OF INFLAMMATORY BOWEL DISEASES | C5AR2, C5AR1, C3AR1 | MAP3K7 2714/4885TAB1 4346/4885 |
| US-20120135923-A1 | Use of Melanocortins to Treat Dyslipidemia | MC4R, MC3R, MC5R | MAP3K7 1650/4885TAB1 3667/4885 |
| US-20210169970-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | MC4R, MC5R, MC3R | MAP3K7 231/4885TAB1 4628/4885 |
| US-20180118784-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | MC4R, MC3R, MC1R | MAP3K7 3469/4885TAB1 4524/4885 |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, IAPP | MAP3K7 2466/4885TAB1 1603/4885 |
| US-20190111105-A1 | Use of Melanocortins to Treat Insulin Sensitivity | MC4R, MC1R, MC3R | MAP3K7 740/4885TAB1 3361/4885 |
| US-20100311647-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | MC4R, MC1R, MC3R | MAP3K7 705/4885TAB1 3641/4885 |
| US-20210163536-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | MC4R, MC3R, MC1R | MAP3K7 3469/4885TAB1 4524/4885 |
| US-10954268-B2 | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | MC4R, MC1R, MC2R | MAP3K7 3918/4885TAB1 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.